N/A
N=294
Smoking Cessation Using Motivational Therapy and Varenicline
Smoking · HIV Infections
Bottom Line
View on ClinicalTrials.gov: NCT00701896 ↗Enrolled (actual)
294
Serious AEs
0.4%
Results posted
Jan 2021
Primary outcome: Primary: To Determine the Safety of Varenicline in PLWH Who Smoke — 13; 38; 3; 4 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Varenicline tartrate (Drug); Nicotine Replacement Therapy (Drug); Biological Control (Other); Motivational Interview (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Philip Diaz
- Primary completion
- Apr 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY To Determine the Safety of Varenicline in PLWH Who Smoke |
13; 38; 3; 4; 11; 8 | — |
| SECONDARY To Determine the Efficacy of Varenicline for Smoking Cessation Among PLWH Who Smoke |
13; 30; 5; 19; 4; 18 | — |
Summary
People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.
Eligibility Criteria
Inclusion Criteria
- 18 years of age and older;
- diagnosis of HIV;
- self-reported smoking on a daily basis;
- provide informed written consent
Exclusion Criteria
- persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam)
- unable to understand spoken English
- age less than 18 years.
- pregnant women
Data sourced from ClinicalTrials.gov (NCT00701896). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.